Development and expression of neuropathic pain in CB1 knockout mice

Neuropharmacology

Volumn 50, Issue 1, 2006, Pages 111-122

  Castañé, Anna ^a   Célérier, Evelyne ^a   Martín, Miquel ^a   Ledent, Catherine ^b   Parmentier, Marc ^b   Maldonado, Rafael ^a   Valverde, Olga ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Allodynia; CB1 cannabinoid receptors; Gabapentin; Hyperalgesia; Neuropathic pain

Indexed keywords

CANNABINOID 1 RECEPTOR; GABAPENTIN;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; GENOTYPE; HYPERALGESIA; KNOCKOUT MOUSE; MALE; MOUSE; NERVE INJURY; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; SCIATIC NERVE;

AMINES; ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; CYCLOHEXANECARBOXYLIC ACIDS; GAMMA-AMINOBUTYRIC ACID; HEAD; HYPERALGESIA; MALE; MICE; MICE, KNOCKOUT; PAIN; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSICAL STIMULATION; RECEPTOR, CANNABINOID, CB1; SCIATIC NEUROPATHY;

EID: 30344440823     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2005.07.022     Document Type: Article

References (47)

1. M. Backonja, and R.L. Glanzman Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials Clin. Ther. 25 2003 81 104
2. J.E. Baños, G. Sánchez, F. Berrendero, and R. Maldonado Neuropathic pain: some clues for future drug treatment Mini Rev. Med. Chem. 3 2003 723 731
3. A.I. Basbaum Distinct neurochemical features of acute and persistent pain Proc. Natl. Acad. Sci. U.S.A. 96 1999 7739 7743
4. G.J. Bennett, and Y.K. Xie A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man Pain 33 1988 87 107
5. L.B. Bortalanza, J. Ferreira, S.C. Hess, F. Delle Monache, R.A. Yunes, and J.B. Calixto Anti-allodynic action of the tormentic acid, a triterpene isolated from plant, against neuropathic and inflammatory persistent pain in mice Eur. J. Pharmacol. 453 2002 203 208
6. D. Bridges, S.W. Thompson, and A.S. Rice Mechanisms of neuropathic pain Br. J. Anaesth. 87 2001 12 26
7. D. Bridges, K. Ahmat, and A.S. Rice The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain Br. J. Pharmacol. 133 2001 586 594
8. A. Castañé, E. Valjent, C. Ledent, M. Parmentier, R. Maldonado, and O. Valverde Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence Neuropharmacology 43 2002 857 867
9. S.R. Chaplan, F.W. Bach, J.W. Pogrel, J.M. Chung, and T.L. Yaksh Quantitative assessment of tactile allodynia in the rat paw J. Neurosci. Methods 53 1994 55 63
10. B. Costa, M. Colleoni, S. Conti, A.E. Trovato, M. Bianchi, M.L. Sotgiu, and G. Giagnoni Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain Br. J. Pharmacol. 141 2004 4 8
11. 1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve Pain 116 2005 52 61
12. B.F. Cravatt, and A.H. Lichtman The endogenous cannabinoid system and its role in nociceptive behavior J. Neurobiol. 61 2004 149 160
13. K.M. Foley Opioids and chronic neuropathic pain N. Engl. J. Med. 348 2003 1279 1281
14. A. Fox, A. Kesingland, C. Gentry, K. McNair, S. Patel, L. Urban, and I. James The role of central and peripheral cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain Pain 92 2001 91 100
15. N.S. Gee, J.P. Brown, V.U. Dissanayake, J. Offord, R. Thurlow, and G.N. Woodruff The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel J. Biol. Chem. 271 1996 5768 5776
16. P. Goya, N. Jagerovic, L. Hernández-Folgado, and M.I. Martin Cannabinoids and neuropathic pain Mini Rev. Med. Chem. 3 2003 765 772
17. K. Hargreaves, R. Dubner, F. Brown, C. Flores, and J. Joris A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia Pain 32 1988 77 88
18. U. Herzberg, E. Eliav, G.J. Bennett, and I.J. Kopin The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain Neurosci. Lett. 221 1997 157 160
19. A.G. Hohmann, and M. Herkenham Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study Neuroscience 90 1999 923 931
20. M.M. Ibrahim, H. Deng, A. Zvonok, D.A. Cockayne, J. Kwan, H.P. Mata, T.W. Vanderah, J. Lai, F. Porreca, A. Makriyannis, and T.P. Malan Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS Proc. Natl. Acad. Sci. U.S.A. 100 2003 10529 10533
21. K.J. Kim, Y.W. Yoon, and J.M. Chung Comparison of three rodent neuropathic pain models Exp. Brain Res. 113 1997 200 206
22. C. Ledent, O. Valverde, G. Cossu, F. Petitet, J.F. Aubert, F. Beslot, G.A. Bohme, A. Imperato, T. Pedrazzini, B.P. Roques, G. Vassart, W. Fratta, and M. Parmentier Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice Science 283 1999 401 404
23. A.H. Lichtman, C.C. Shelton, T. Advani, and B.F. Cravatt Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia Pain 109 2004 319 327
24. G. Lim, B. Sung, R.-R. Ji, and J. Mao Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of win55,212-2 on neuropathic pain behaviours in rats Pain 105 2003 275 283
25. W. Löscher, D. Honack, and C.P. Taylor Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain Neurosci. Lett. 128 1991 150 154
26. M. Maizels, and B. McCarberg Antidepressants and antiepileptic drugs for chronic non-cancer pain Am. Fam. Physician 71 2005 483 490
27. T.P. Malan Jr., M.M. Ibrahim, J. Lai, T.W. Vanderah, A. Makriyannis, and F. Porreca CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr. Opin. Pharmacol. 3 2003 62 67
28. T.P. Malan Jr., M.M. Ibrahim, T.W. Vanderah, A. Makriyannis, and F. Porreca Inhibition of pain responses by activation of CB(2) cannabinoid receptors Chem. Phys. Lipids 121 2002 191 200
29. A.B. Malmberg, and A.I. Basbaum Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates Pain 76 1998 215 222
30. J. Mao, D.D. Price, J. Lu, L. Keniston, and D.J. Mayer Two distinctive antinociceptive systems in rats with pathological pain Neurosci. Lett. 280 2000 13 16
31. F. Massa, G. Marsicano, H. Hermann, A. Cannich, K. Monory, B.F. Cravatt, G.L. Ferri, A. Sibaev, M. Storr, and B. Lutz The endogenous cannabinoid system protects against colonic inflammation J. Clin. Invest. 113 2004 1202 1209
32. H.J. McQuay, M. Tramer, B.A. Nye, D. Carroll, P.J. Wiffen, and R.A. Moore A systematic review of antidepressants in neuropathic pain Pain 68 1996 217 227
33. S. Patel, S. Naeem, A. Kesingland, W. Froestl, M. Capogna, L. Urban, and A. Fox The effects of GABA(B) agonists and gabapentin on mechanical hyperalgesia in models of neuropathic and inflammatory pain in the rat Pain 90 2001 217 226
34. R.G. Pertwee Cannabinoid receptors and pain Prog. Neurobiol. 63 2001 569 611
35. D. Piomelli, A. Giuffrida, A. Caignano, and F. Rodríguez de Fonseca The endocannabinoid system as a target for therapeutic drugs Trends Pharmacol. Sci. 21 2000 218 224
36. M.A. Rogawski, and W. Loscher The neurobiology of antiepileptic drugs Nat. Rev. Neurosci. 5 2004 553 564
37. M.C. Rowbotham Chronic pain: from theory to practical management Neurology 45 1995 S5 S10
38. D.A. Scott, C.E. Wright, and J.A. Angus Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat Pain 109 2004 124 131
39. Z. Seltzer, R. Dubner, and Y. Shir A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury Pain 43 1990 205 218
40. A. Siegling, H.A. Hofmann, D. Denzer, F. Mauler, and J. De Vry Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain Eur. J. Pharmacol. 415 2001 R5 R7
41. S.H. Sindrup, and T.S. Jensen Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action Pain 83 1999 389 400
42. E. Spina, and G. Perugi Antiepileptic drugs: indications other than epilepsy Epileptic Disord. 6 2004 57 75
43. S. Stander, M. Schmelz, D. Metze, T. Luger, and R. Rukwied Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin J. Dermatol. Sci. 38 2005 177 188
44. O. Valverde, C. Ledent, F. Beslot, M. Parmentier, and B.P. Roques Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors Eur. J. Neurosci. 12 2000 533 539
45. J.N. Wood, B. Abrahamsen, M.D. Baker, J.D. Boorman, E. Donier, L.J. Drew, M.A. Nassar, K. Okuse, A. Seereeram, C.L. Stirling, and J. Zhao Ion channel activities implicated in pathological pain Novartis Found. Symp. 261 2004 32 40 discussion 32-40
46. J. Zhang, C. Hoffert, H.K. Vu, T. Groblewski, S. Ahmad, and D. O'Donnell Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models Eur. J. Neurosci. 17 2003 2750 2754
47. A. Zimmer, A.M. Zimmer, A.G. Hohmann, M. Herkenham, and T.I. Bonner Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice Proc. Natl. Acad. Sci. U.S.A. 96 1999 5780 5785